Rodney J Hicks1,2, Price Jackson3, Grace Kong3, Robert E Ware3, Michael S Hofman3,2, David A Pattison3, Timothy A Akhurst3, Elizabeth Drummond3, Peter Roselt3, Jason Callahan3, Roger Price4, Charmaine M Jeffery4, Emily Hong3, Wayne Noonan5, Alan Herschtal6, Lauren J Hicks7, Amos Hedt8, Matthew Harris8, Brett M Paterson9, Paul S Donnelly10. 1. Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia rod.hicks@petermac.org. 2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. 3. Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 4. Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Washington, Australia. 5. Liverpool Hospital, Liverpool, New South Wales, Australia. 6. Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 7. Mercy Hospital for Women, Heidelberg, Victoria, Australia rod.hicks@petermac.org. 8. Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia. 9. School of Chemistry, Monash University, Victoria, Australia; and. 10. School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.
Abstract
Imaging of somatostatin receptor expression is an established technique for staging of neuroendocrine neoplasia and determining the suitability of patients for peptide receptor radionuclide therapy. PET/CT using 68Ga-labeled somatostatin analogs is superior to earlier agents, but the rapid physical decay of the radionuclide poses logistic and regulatory challenges. 64Cu has attractive physical characteristics for imaging and provides a diagnostic partner for the therapeutic radionuclide 67Cu. Based on promising preclinical studies, we have performed a first-time-in-humans trial of 64Cu-MeCOSar-Tyr3-octreotate (64Cu-SARTATE) to assess its safety and ability to localize disease at early and late imaging time-points. Methods: In a prospective trial, 10 patients with known neuroendocrine neoplasia and positive for uptake on 68Ga-DOTA-octreotate (68Ga-DOTATATE) PET/CT underwent serial PET/CT imaging at 30 min, 1 h, 4 h, and 24 h after injection of 64Cu-SARTATE. Adverse reactions were recorded, and laboratory testing was performed during infusion and at 1 and 7 d after imaging. Images were analyzed for lesion and normal-organ uptake and clearance to assess lesion contrast and perform dosimetry estimates. Results: 64Cu-SARTATE was well tolerated during infusion and throughout the study, with 3 patients experiencing mild infusion-related events. High lesion uptake and retention were observed at all imaging time-points. There was progressive hepatic clearance over time, providing the highest lesion-to-liver contrast at 24 h. Image quality remained high at this time. Comparison of 64Cu-SARTATE PET/CT obtained at 4 h to 68Ga-DOTATATE PET/CT obtained at 1 h indicated comparable or superior lesion detection in all patients, especially in the liver. As expected, the highest early physiologic organ uptake was in the kidneys, liver, and spleen. Conclusion: 64Cu-SARTATE is safe and has excellent imaging characteristics. High late-retention in tumor and clearance from the liver suggest suitability for diagnostic studies and for prospective dosimetry for 67Cu-SARTATE peptide receptor radionuclide therapy, and the half-life of 64Cu would also facilitate good-manufacturing-practice production and distribution to sites without access to 68Ga.
Imaging of somatostatin receptor expression is an established technique for staging of neuroendocrine neoplasia and determining the suitability of patients for peptide receptor radionuclide therapy. PET/CT using 68Ga-labeled somatostatin analogs is superior to earlier agents, but the rapid physical decay of the radionuclide poses logistic and regulatory challenges. 64Cu has attractive physical characteristics for imaging and provides a diagnostic partner for the therapeutic radionuclide 67Cu. Based on promising preclinical studies, we have performed a first-time-in-humans trial of 64Cu-MeCOSar-Tyr3-octreotate (64Cu-SARTATE) to assess its safety and ability to localize disease at early and late imaging time-points. Methods: In a prospective trial, 10 patients with known neuroendocrine neoplasia and positive for uptake on 68Ga-DOTA-octreotate (68Ga-DOTATATE) PET/CT underwent serial PET/CT imaging at 30 min, 1 h, 4 h, and 24 h after injection of 64Cu-SARTATE. Adverse reactions were recorded, and laboratory testing was performed during infusion and at 1 and 7 d after imaging. Images were analyzed for lesion and normal-organ uptake and clearance to assess lesion contrast and perform dosimetry estimates. Results:64Cu-SARTATE was well tolerated during infusion and throughout the study, with 3 patients experiencing mild infusion-related events. High lesion uptake and retention were observed at all imaging time-points. There was progressive hepatic clearance over time, providing the highest lesion-to-liver contrast at 24 h. Image quality remained high at this time. Comparison of 64Cu-SARTATE PET/CT obtained at 4 h to 68Ga-DOTATATE PET/CT obtained at 1 h indicated comparable or superior lesion detection in all patients, especially in the liver. As expected, the highest early physiologic organ uptake was in the kidneys, liver, and spleen. Conclusion:64Cu-SARTATE is safe and has excellent imaging characteristics. High late-retention in tumor and clearance from the liver suggest suitability for diagnostic studies and for prospective dosimetry for 67Cu-SARTATE peptide receptor radionuclide therapy, and the half-life of 64Cu would also facilitate good-manufacturing-practice production and distribution to sites without access to 68Ga.
Authors: Stefan Klein; Marius Staring; Keelin Murphy; Max A Viergever; Josien P W Pluim Journal: IEEE Trans Med Imaging Date: 2009-11-17 Impact factor: 10.048
Authors: Heather Ann Williams; Simon Robinson; Peter Julyan; Jamal Zweit; David Hastings Journal: Eur J Nucl Med Mol Imaging Date: 2005-10-29 Impact factor: 9.236
Authors: Stanislas Pauwels; Raffaella Barone; Stéphan Walrand; Françoise Borson-Chazot; Roelf Valkema; Larry K Kvols; Eric P Krenning; François Jamar Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057
Authors: Dik J Kwekkeboom; Wouter W de Herder; Casper H J van Eijck; Boen L Kam; Martijn van Essen; Jaap J M Teunissen; Eric P Krenning Journal: Semin Nucl Med Date: 2010-03 Impact factor: 4.446
Authors: Melpomeni Fani; Luigi Del Pozzo; Keelara Abiraj; Rosalba Mansi; Maria Luisa Tamma; Renzo Cescato; Beatrice Waser; Wolfgang A Weber; Jean Claude Reubi; Helmut R Maecke Journal: J Nucl Med Date: 2011-06-16 Impact factor: 10.057
Authors: C J Anderson; F Dehdashti; P D Cutler; S W Schwarz; R Laforest; L A Bass; J S Lewis; D W McCarthy Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: Ka Kit Wong; Kirk A Frey; Jeremy Niedbala; Ravi K Kaza; Francis P Worden; Kellen J Fitzpatrick; Yuni K Dewaraja Journal: Nucl Med Commun Date: 2022-06-10 Impact factor: 1.698
Authors: Alexandra I Fonseca; Vítor H Alves; Sérgio J C do Carmo; Magda Silva; Ivanna Hrynchak; Francisco Alves; Amílcar Falcão; Antero J Abrunhosa Journal: Pharmaceuticals (Basel) Date: 2022-06-07
Authors: Lachlan E McInnes; Carleen Cullinane; Peter D Roselt; Susan Jackson; Benjamin J Blyth; Ellen M van Dam; Nicholas A Zia; Matthew J Harris; Rodney J Hicks; Paul S Donnelly Journal: J Nucl Med Date: 2020-10-16 Impact factor: 10.057
Authors: Stacey E Rudd; Jessica K Van Zuylekom; Anna Raicevic; Lesley A Pearce; Carleen Cullinane; Charlotte C Williams; Timothy E Adams; Rodney J Hicks; Paul S Donnelly Journal: Chem Sci Date: 2021-05-25 Impact factor: 9.825